Fewer than 1% of docs sees bias in online CME, survey finds

Share this article:
A Medscape-sponsored survey of a million physicians participating in online CME found that fewer than 1% perceived bias, regardless of whether or not it was commercially supported.

Overall, 93.48% of the 1,064,642 respondents said didn't perceive bias in the CME they participated in, with another 5.89% expressing no opinion and only .63% saying they did sense bias. Of those participating in commercially-supported CME, .84% perceived bias, while .48% of those participating in non-commercially–supported CME sensed bias.

The survey asked participants to indicate whether they agreed or disagreed, strongly or not, with the statement “The activity was presented objectively and free of commercial bias.” The number of those strongly disagreeing was just .14% overall—.17% of those participating in commercially-supported CME and 11% of those taking part in non-commercially supported CME.

“If commercial support caused bias, our subgroup analysis of those who strongly disagreed would be expected to show a larger difference, not the smaller difference we observed,” wrote the study's authors.

The study appears in the September issue of The American Journal of Medicine. Its sponsor, WebMD's Medscape, is a leading provider of online CME, and data came from physicians taking part in online CME through the site. Of 1,621,647 physician participants, around 66% completed the survey
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...